Tumor Biology for the Clinician: Melanoma Peptide Vaccines

Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 1943; 3: 326–333.

Shu S. , Chou T. , Rosenberg S.A. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol. 1986; 136: 3891–3898.

Rosenberg S.A. , Packard B.S. , Aebersold P.M. Use of tumor- infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988; 319: 1676–1680.

Berd D. , Maguire H.C. Jr , McCue P. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990; 8: 1858–1867.

Mitchell M.S. , Habel W. , Kan-Mitchell J. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci. 1993; 690: 153–166.

Kawakami Y. , Eliyahu S. , Delgado C.H. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994; 91: 6458–6462.

Wallack M.K. , Sivanandham M. , Balch C.M. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995; 75: 34–42.

Bumol T.F. , Harper J.R. , Chee D.O. Antigenic expression of human melanoma cells in serum-free medium. Adv Exp Med Biol. 1984; 172: 455–470.

Cheresh D.A. , Honsik C.J. , Staffileno L.K. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody–mediated tumor cytolysis. Proc Natl Acad Sci U S A. 1985; 82: 5155–5159.

Yamaguchi H. , Furukawa K. , Fortunato S.R. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A. 1987; 84: 2416–2420.

Reisfeld R.A. Antigen repertoire of human melanoma. Prog Clin Biol Res. 1988; 256: 343–360.

Livingston P.O. , Adluri S. , Helling F. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 1994; 12: 1275–1280.

Townsend S.E. , Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993; 259: 368–370.

Ramarathinam L. , Castle M. , Wu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med. 1994; 179: 1205–1214.

Hersey P. , Si Z. , Smith M.J. Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer. 1994; 58: 527–532.

Rosenberg S.A. , Yannelli J.R. , Yang J.C. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86: 1159–1166.

Darrow T.L. , Slingluff C.L. Jr , Seigler H.F. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol. 1989; 142: 3329–3335.

Slingluff C.L. Jr , Cox A.L. , Henderson R.A. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol. 1993; 150: 2955–2963.

Huang A.Y. , Golumbek P. , Ahmadzadeh M. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994; 264: 961–965.

Chen Q. , Hersey P. MHC-restricted responses of CD8+ and CD4+ T-cell clones from regional lymph nodes of melanoma patients. Int J Cancer. 1992; 51: 218–224.

Hom S.S. , Topalian S.L. , Simonis T. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother. 1991; 10: 153–164.

Blieden T.M. , McAdam A.J. , Frelinger J.G. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol. 1991; 147: 1433–1438.

D'Alessandro G. , Zardawi I. , Grace J. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma. Pathology. 1987; 19: 339–346.

Levitsky H.I. , Lazenby A. , Hayashi R.J. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994; 179: 1215–1224.

Vegh Z. , Wang P. , Vanky F. Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res. 1993; 53(Suppl 10): 2416–2420.

Knuth A. , Wolfel T. , Klehmann E. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A. 1989; 86: 2804–2808.

Seung S. , Urban J.L. , Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993; 178: 933–940.

Restifo N.P. , Esquivel F. , Kawakami Y. Identification of human cancers deficient in antigen processing. J Exp Med. 1993; 177: 265–272.

Townsend A. , Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989; 7: 601–624.

Traversari C. , van der Bruggen P. , Luescher I.F. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992; 176: 1453–1457.

van der Bruggen P. , Szikora J.P. , Boel P. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 1994; 24: 2134–2140.

Zakut R. , Topalian S.L. , Kawakami Y. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res. 1993; 53: 5–8.

van der Bruggen P. , Traversari C. , Chomez P. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 1643–1647.

Boon T. , Cerottini J.C. , Van den Eynde B. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12: 337–365.

Gaugler B. , Van den Eynde B. , van der Bruggen P. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994; 179: 921–930.

Celis E. , Tsai V. , Crimi C. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994; 91: 2105–2109.

Brichard V. , Van Pel A. , Wolfel T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993; 178: 489–495.

Wolfel T. , Van Pel A. , Brichard V. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994; 24: 759–764.

Cox A.L. , Skipper J. , Chen Y. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994; 264: 716–719.

Robbins P.F. , el-Gamil M. , Kawakami Y. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994; 54: 3124–3126.

Topalian S.L. , Rivoltini L. , Mancini M. Human CD4+ T-cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A. 1994; 91: 9461–9465.

Bakker A.B. , Schreurs M.W. , de Boer A.J. Melanoma lineage-specific antigen gpl00 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994; 179: 1005–1009.

Smoller B.R. , Hsu A. , Krueger J. HMB-45 monoclonal antibody recognizes an inducible and reversible melanocyte cytoplasmic protein. J Cutan Pathol. 1991; 18: 315–322.

Colombari R. , Bonetti F. , Zamboni G. Distribution of melanoma- specific antibody (HMB-45) in benign and malignant melanocytic tumours: an immunohistochemical study on paraffin sections. Virchows Arch Pathol Anat Histopathol. 1988; 413: 17–24.

Adema G.J. , de Boer A.J. , van't Hullenaar R. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, HMB-45 are encoded by a single cDNA. Am J Pathol. 1993; 143: 1579–1585.

Vennegoor C. , Hageman P. , Van Nouhuijs H. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol. 1988; 130: 179–192.

Kawakami Y. , Eliyahu S. , Sakaguchi K. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180: 347–352.

Kwon B.S. , Halaban R. , Kim G.S. A melanocyte-specific complementary DNA clone whose expression is inducible by melanotropin and isobutylmethylxanthine. Mol Biol Med. 1987; 4: 339–355.

Kwon B.S. , Chintamaneni C. , Kozak C.A. A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc Natl Acad Sci U S A. 1991; 88: 9228–9232.

Kawakami Y. , Eliyahu S. , Delgado C.H. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994; 91: 3515–3519.

Coulie P.G. , Brichard V. , Van Pel A. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180: 35–42.

Bystryn J.C. , Rigel D. , Friedman R.J. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987; 123: 1053–1055.

Nordlund J.J. , Kirkwood J.M. , Forget B.M. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983; 9: 689–696.

Anichini A. , Maccalli C. , Mortarini R. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993; 177: 989–998.

Boon T. Genes encoding tumor rejection antigens. Presented at Tumor Immunology Symposium; May 23, 1994; Charlottesville, Va.

Schwartz R.H. Acquisition of immunologic self-tolerance. Cell. 1989; 57: 1073–1081.